1061-93 Granulocyte-colony stimulating factor induced mobilization and intra-coronary infusion of mobilized whole leukocyte is a feasible, safe method of stem cell transplantation in patients with myocardial infarction  by Kang, Hyun-Jae et al.
264A ABSTRACTS - Myocardial Ischemia and Infarction JACC March 3, 2004
M
yo
ca
rd
ia
l I
sc
he
m
ia
 a
nd
 In
fa
rc
tio
n
in the unloaded animals (202.17 ± 49.89 pg/100µl vs 15.29 ± 8.45 pg/100 µl respec-
tively). Greater contraction band necrosis with edema and interstitial hemorrhage was
observed in the ischemic and infarct regions of the control dogs compared to the
unloaded animals. In the central ischemic region of the treated animals, we counted an
average of 410 nuclei; 22.81 ± 6.4 % displayed TUNEL-positive staining. In contrast, for
the same amount of nuclei counted 35.18 ± 5.17% displayed TUNEL-positive staining in
the ischemic region of the control animals.
Conclusions: Mechanical LV unloading, just prior to reperfusion reduces coronary sinus
plasma ET-1 levels immediately after reperfusion and limits the extent of contraction band
necrosis and the loss of cardiomyocytes through apoptosis in the central ischemic region
in a canine ischemia-reperfusion model.
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Background: Prognosis in acute myocardial infarction (AMI) is mainly determined by
early reperfusion and restoration of a normal flow in the infarct related artery. However,
reperfusion therapy for AMI with thrombolysis has been shown to achieve a 50-60%
TIMI-3-flow only. Early trials combining thrombolysis and PTCA have failed to show a
mortality benefit mainly as a cause of encountered bleeding complications. New pharma-
cological developments might allow a facilitated PCI approach initiated in the prehospital
setting.
Methods: Since 12/2000 151 patients with an AMI were randomized within 6 hours after
symptom onset to either a prehospital COMBO (half dose Reteplase + abciximab) with
in-hospital conservative therapy (n=75) or a prehospital initiated COMBO therapy with
immediate in-hospital "facilitated" PCI (n=76). Primary endpoints were ST-segment reso-
lution at 90 min., infarct size expressed as area under the curve of CK-release and as
delayed enhancement MRI. The secondary endpoint was a composite of mortality, re-
AMI, major bleeding and stroke.
Results: Mean time from symptom onset to arrival of the emergency physician was 109±
80 min. in COMBO only in comparison to 106± 40 min. in the facilitated PCI-group
(p=n.s.). In the facilitated PCI-group TIMI-3-flow before intervention was 65% and after
96%, respectively. 90-min ST-segment resolution was more complete in the facilitated
PCI group (57± 48% vs. 83± 23%, p<0.001). Infarct size measured by CK-release was
873± 854 in the COMBO only versus 617± 400 µ mol/l/h in the facilitated PCI-group
(p=0.02) and 12± 11% versus 7± 6% of the left ventricular mass in the delayed enhance-
ment MRI (p=0.005). In the secondary combined endpoint there was a trend towards a
lower event rate in the facilitated PCI group. (31% vs. 20%, p=0.18).
Conclusion: "Facilitated" PCI after prehospital initiated combination thrombolysis results
in a an improved tissue perfusion as shown by the ST-segment resolution, which leads to
smaller infarct sizes. As a consequence there is a trend towards a lower clinical event
rate.
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Background: It is unknown whether thrombolytic administration before angioplasty (PCI)
for acute myocardial infarction (AMI) is superior to primary PCI. The aim of the study was
to evaluate the relationship between symptom-onset-to-PCI time and 2-year outcome in
patients (pts) transferred to primary PCI or PCI facilitated with thrombolysis.
Methods: A total of 368 consecutive pts (cardiogenic shock pts excluded) were included
in the analysis. Thrombolysis was administered in the referral hospitals in 180 (49%) of
pts when the anticipated time to PCI exceeded 60 minutes.
Results: In primary PCI, symptom-onset-to-PCI time was negatively associated with left
ventricle ejection fraction (p = 0.013), but was not in facilitated PCI. Two-year incidence of
death, myocardial infarction or stroke (MACE) in relation to symptom-onset-to-PCI time is
shown in the figure. At multivariate analysis, administration of thrombolytic in patients
with symptom-onset-to-PCI time <= 4 h was an independent predictor of MACE (relative
risk = 2.55; 95% confidence interval = 1.16-5.63). Oppositely, in patients with symptom-
onset-to-PCI time > 4 h, thrombolysis was associated with good prognosis (relative risk
of MACE = 0.45; 95% confidence interval = 0.22-0.91).
Conclusion: This study supports the idea of thrombolytic treatment before angioplasty
but only in patients with PCI performed after 4 hours of pain. Utilization of thrombolysis
before PCI performed up to 4 hours from the onset of AMI could worsen the outcome.
1061-93 Granulocyte-Colony Stimulating Factor Induced 
Mobilization and Intra-Coronary Infusion of Mobilized 
Whole Leukocyte Is a Feasible, Safe Method of Stem 
Cell Transplantation in Patients With Myocardial 
Infarction
Hyun-Jae Kang, Hyo-Soo Kim, Hyun-Jai Cho, Bon-kuen Koo, Yong-Jin Kim, Dae-Won 
Sohn, Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-Shik Choi, Seoul 
National University College of Medicine, Seoul, South Korea, Seoul National University 
Hospital, Seoul, South Korea
Background: Beneficial effects of bone marrow stem cell transplantation in patients with
MI brought the need of noninvasive stem cell mobilization. Safety and feasibility of G-
CSF induced stem cell mobilization and mobilized cell infusion is unknown. We tested the
clinical feasibility and effects of G-CSF induced mobilization and intra-coronary infusion
in patients with MI.
Methods: We randomly allocated 22 patients (56 ± 11years old, LVEF =50 ± 12%) into
three groups: 1) G-CSF group: G-CSF induced mobilization (n= 10, 6 AMI patients), 2)
Infusion group: intra-coronary infusion of G-CSF mobilized cells (n = 10, 4 AMI patients),
3) Non-mobilization group (n=2, 2 AMI patients). G-CSF with 10ug/kg/day for 4.2 ± 0.7
days were administrated to G-CSF and infusion group. And then all groups underwent
percutaneous coronary intervention (PCI) for culprit lesion. MIBI SPECT and PET were
performed before PCI and treadmill test and dobutamine stress echo were performed
after PCI. Follow up coronary angiography and noninvasive studies were performed after
6 months later.
Results: Patients in each study group showed no significant differences in baseline char-
acteristics. No adverse reaction was observed except mild headache (3 patients) with G-
CSF administration. Patients in infusion group underwent apheresis before PCI and 1.5 ±
0.5 x 109 leukocytes (7.6 ± 2.9 x 107 CD 34+ cells) were infused after PCI without compli-
cation. Elevation of CK-MB after PCI were comparable among study groups (Before and
12hours after PCI, Infusion group: 2.2 ± 2.2 vs. G-CSF group: 0.3 ± 3.1 vs. Non-mobiliza-
tion group: 1.5 ± 0.7U/L, p=0.34). Symptom and ECG had not changed after PCI. No
reflow phenomenon was not observed and coronary flow reserve did not worsened with
cell infusion (before and 10minutes after infusion: 1.7 ± 0.4 vs. 1.7 ± 0.5: p=0.75). Three
symptomatic restenosis(one from cell infusion group and two from G-CSF group) were
observed during mean 4 ± 1month clinical follow up.
Conclusions: G-CSF is a feasible and safe stem cell mobilizer in MI. Apheresis and whole
leukocyte infusion after G-CSF mobilization is a practical method of stem cell transplan-
tation.
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Background: Recent studies have shown that carvedilol reduces all-cause mortality in
patients with left ventricular dysfunction after acute myocardial infarction (AMI). However,
the mechanisms remain unknown. We serially studied the effects of carvedilol on both
Left ventricular function and myocardial perfusion after AMI. Method: Seventy-eight
patients (61.3±9.6 years, 64 males) who underwent successful percutaneous coronary
intervention for AMI were recruited to this study. They were divided into two groups:
carvedilol (5-20 mg, daily) group (N=39) and infarct-related artery matched control group
(N=39). Tc-99m tetrofosmin ECG-gated SPECT imaging (TF) was performed 7-10 days
after the onset (baseline). Left ventricular ejection fraction (LVEF) was obtained from TF
using automated quantitative method. The myocardium was divided into 17 segments for
analysis of regional perfusion and segmental score was graded by 5 degrees according
to the relative activity against normal perfusion segment (0: normal, 4: defect). Follow-up
TF study was performed 3 months (chronic) after onset to identify the improvements of
LVEF and myocardial perfusion. Result: Baseline characteristics (carvedilol group versus
control group; age: 61.8±10.4 years versus 60.9±8.9 years, peak CPK: 4475±2629 IU/l
versus 4084±2186 IU/l) were similar in both groups. In baseline TF, LVEF (carvedilol
group 43.3% versus control group 46.4%), the total of defect scores (TDS) (19.6 ±9.3
versus 16.6±6.8) and the number of hypo-perfusion (score grade >1) segments (HS)
(10.2±3.0 versus 9.4±2.6) did not differ significantly. However, in chronic TF, improvement
of LVEF from baseline is significantly greater in carvedilol group than that in control group
(carvedilol group +7.6% versus control group +0.4%, p=0.0004). Moreover, TDS and HS
were significantly decreased from baseline in only carvedilol group (TDS: carvedilol
group -2.8 Versus control group +1.1, p=0.001, HS: -1.2 Versus +0.4, p=0.004). Conclu-
sion: Carvedilol after primary percutaneous coronary intervention improves myocardial
perfusion and left ventricular function in AMI. This result may explain the beneficial effect
of carvedilol treatment.
